Invesaro

Stocks Health care TRAW

NASDAQ · Health care

Traws Pharma, Inc. (TRAW)

It posted a net loss of $21.6M. In fiscal 2024 capital spending exceeded operating cash flow by $20.8M. At June 30, 2026 it held $5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What Traws Pharma, Inc. does

Traws Pharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRAW.

Revenue and profit by year

Revenue
FY18: $1.2M $1.2M FY18FY19: $2.2M $2.2M FY19FY20: $231K $231K FY20FY21: $226K $226K FY21FY22: $226K $226K FY22FY23: $226K $226K FY23FY24: $226K $226K FY24FY24: $2.8M $2.8M FY24
Net income
FY18: -$20.6M -$20.6M FY18FY19: -$21.5M -$21.5M FY19FY20: -$25.2M -$25.2M FY20FY21: -$16.2M -$16.2M FY21FY22: -$19M -$19M FY22FY23: -$18.9M -$18.9M FY23FY24: -$166.5M -$166.5M FY24FY24: $9.2M $9.2M FY24

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2024$2.8M-$17.9M$9.2M$0.82-$20.8M
2024$226K-$142.4M-$166.5M-$35.21-$33.4M
2023$226K-$20.3M-$18.9M-$22.57-$17.9M
2022$226K-$19.6M-$19M-$22.82n/a
2021$226K-$16.5M-$16.2M-$24.07n/a
2020$231K-$25M-$25.2M-$54.42-$23.1M

Full financial statements: income, balance sheet and cash flow

Next report expected around October 14, 2026.

Estimated from its filing rhythm: about 61 days after its last report of August 14, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where TRAW ranks in Health care

Revenue$2.8M
#534 of 646 in Health care · Bottom 17%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Traws Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
  2. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.16 versus -$0.11.
  3. August 14, 2026
  4. August 14, 2026
  5. August 14, 2026
  6. August 12, 2026
  7. July 31, 2026
  8. July 10, 2026
  9. July 10, 2026
  10. July 9, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 16, 2026. Insider transactions on SEC

Insider trades

What the people running Traws Pharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TRAW

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Orbimed Advisors LLC13D, may seek influence with 1 related filers 11.9% 1,876,198 May 5, 2026
Sirenia Capital Management LP13G, passive with 1 related filers 9.9% 6,565,474 August 14, 2026
Ikarian Capital, LLC13G, passive with 1 related filers 9.5% 1,555,423 August 14, 2026
Perceptive Advisors LLC13G, passive with 2 related filers 6.1% 979,815 May 15, 2026

Latest filings below 5%: Squadron Master Fund LP 0% (August 14, 2026); Adage Capital Management, L.P. 4.79% (August 12, 2026); Ayrton Capital LLC 4.29% (February 11, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TRAW

What does Traws Pharma, Inc. do?

Traws Pharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRAW.

Is Traws Pharma, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $21.6M.

When did Traws Pharma, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Compare TRAW with

Compare TRAW with any company

Follow TRAW

Get an email when Traws Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TRAW: get an email when it files

Where the numbers come from

Financial figures are the values Traws Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.